Abstracts tagged "scleroderma and treatment"

Abstract Number: 1851 • 2016 ACR/ARHP Annual Meeting
The Effect of Narrow Band Ultraviolet A1 Light on Bleomycin-Induced Mouse Model of Scleroderma
Diana Karpec^1,2, Romualdas Rudys², Laima Leonaviciene², Zygmunt Mackiewicz², Ruta Bradunaite², Gailute Kirdaite², Rita Rugiene² and Algirdas Venalis^2,3, ¹Clinics of Rheumatology, Traumatology-Orthopedics and Reconstructive Surgery, Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania, ²State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania, ³Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania
Background/Purpose: Ultraviolet A1 (UVA1) phototherapy implications for systemic sclerosis still remain the area of research. The aim of the study was to evaluate narrow band…
Abstract Number: 3095 • 2015 ACR/ARHP Annual Meeting
Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study
Suzanne C. Li¹, Kathryn S. Torok², Sandy D. Hong³, Polly J. Ferguson⁴, C. Egla Rabinovich⁵, Mara L Becker⁶, Fatma Dedeoglu⁷, Maria F. Ibarra⁸, Robert C. Fuhlbrigge^9,10, Katie G. Stewart¹¹, Marilynn G. Punaro¹¹, Thomas Mason II¹², Elena Pope¹³, Ronald Laxer¹⁴, Gloria C. Higgins^15,16 and Brian Feldman¹⁷, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ⁴Dept of Pediatrics--Rheum, University of Iowa, Iowa City, IA, ⁵Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, ⁶Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁷Rheumatology, Boston Children's Hospital, Boston, MA, ⁸Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁹Program in Rheumatology, Division of Immunology, Boston Children’s Hospital, Boston, MA, ¹⁰Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Rheumatology, Mayo Clinic, Rochester, MN, ¹³Dermatology, Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Pediatric Rheumatology OSU, Nationwide Childrens Hosp, Columbus, OH, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hospital, Columbus, OH, ¹⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease that causes severe morbidity, including growth defects, cosmetic deformities, seizures and arthropathy.…
Abstract Number: 1701 • 2014 ACR/ARHP Annual Meeting
Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry
Florenzo Iannone, Cinzia Rotondo, Mariangela Nivuori, Emanuela Praino, Laura Coladonato, Michele Covelli and Giovanni Lapadula, DIM, Rheumatology Unit, Bari, Italy
Background/Purpose Iloprost is a milestone in the treatment of Raynaud’s Phenomenon (RP). However, it has transient hemodynamic effects due to a very short half-time, thereby…
Abstract Number: 1325 • 2014 ACR/ARHP Annual Meeting
Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE): Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Localized Scleroderma and Juvenile Systemic Sclerosis
Bas Vastert¹, Roberta Culpo², Jordi Anton³, Tadej Avcin⁴, Eileen Baildam⁵, Christina Boros⁶, Tamás Constantin⁷, Jeff Chaitow⁸, Pavla Dolezalova⁹, Ozgur Kasapcopur¹⁰, Sheila Oliveira¹¹, Clarissa Pilkington¹², Annet van Royen-Kerkhof¹³, Ricardo A. G. Russo¹⁴, Claudia Saad-Magalhaes¹⁵, Natasa Toplak¹⁶, Angelo Ravelli¹⁷, Nico Wulffraat¹⁸, Ivan Foeldvari¹⁹ and Francesco Zulian²⁰, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Pediatrics., University of Padua, Padua, Italy, ³Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, ⁴Pediatric Rheumatology, University Children´s Hospital, Ljubjana, Slovenia, ⁵Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁶University of Adelaide, Adelaide, Australia, ⁷Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁸The Children’s Hospital Westmead, Sydney, Australia, ⁹Department of Paediatrics and Adolescent Medicine, Charles University, Prague, Czech Republic, ¹⁰University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ¹¹Pediatric Rheumatology, Universidade F Rio De Janeiro, Rio De Janeiro, Brazil, ¹²Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ¹³Paediatric Immunology and Rheumatology, University Medical Centre Utrecht - Wilhelmina Children's Hospital, Utrecht, Netherlands, ¹⁴Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ¹⁵Faculdade de Medicina de Botucatu, Botucatu, Brazil, ¹⁶Pediatric Rheumatology, University Medical Center, Ljubliana, Slovenia, ¹⁷Istituto Giannina Gaslini and University of Genova, Genova, Italy, ¹⁸Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, ¹⁹Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ²⁰Pediatrics/Rheumatology Div, University of Padua, Padua, Italy
Background/Purpose Juvenile Localized Scleroderma (JLS) and Juvenile Systemic Sclerosis (JSSc) form a group of rare pediatric diseases that can lead to significant morbidity. Evidence-based guidelines…
Abstract Number: 1324 • 2014 ACR/ARHP Annual Meeting
Predictors of Disease Relapse in Juvenile Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski² and Christina Kelsey³, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA
Background/Purpose Localized scleroderma (LS) is an autoimmune disease characterized by inflammation of the skin and underlying tissue leading tissue damage including atrophy, dyspigmentation, and fibrosis. …
Abstract Number: 1321 • 2014 ACR/ARHP Annual Meeting
A Pilot Study to Evaluate the Feasibility of Conducting Juvenile Localized Scleroderma Comparative Effectiveness Treatment Studies
Suzanne C. Li¹, Kathryn S. Torok², Mara L Becker^3,4, Fatma Dedeoglu⁵, Polly J. Ferguson⁶, Robert C. Fuhlbrigge^7,8, Gloria C. Higgins⁹, Sandy D. Hong¹⁰, Maria F. Ibarra¹¹, Ronald Laxer¹², Thomas G. Mason II¹³, Elena Pope¹⁴, Marilynn G. Punaro¹⁵, C. Egla Rabinovich¹⁶, Katie G. Stewart¹⁵ and Brian Feldman¹⁷, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁴Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁵Rheumatology, Boston Children's Hospital, Boston, MA, ⁶Dept of Pediatrics--Rheum, University of Iowa Carver College of Medicine, Iowa City, IA, ⁷Department of Dermatology, Brigham and Women's Hospital, Boston, MA, ⁸Division of Immunology, Boston Children's Hospital, Boston, MA, ⁹Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁰Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ¹¹Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ¹²Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ¹³Rheumatology, Mayo Clinic Rochester, Rochester, MN, ¹⁴Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁶Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, ¹⁷Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose Juvenile localized scleroderma (jLS) often causes severe morbidity in the developing child, including growth defects and disfigurement. Optimal therapy is not known. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].